Macrolides are a class of antibiotics used to treat common bacterial infections like pneumonia, sinusitis, strep throat, and ear infections. The three you’re most likely to encounter are erythromycin, clarithromycin, and azithromycin (often sold as a Z-Pack). They work by stopping bacteria from making the proteins they need to grow, and they’re especially useful for people who are allergic to penicillin.
How Macrolides Work
Every bacterium needs to build proteins to survive and multiply. It does this using tiny molecular machines called ribosomes, which read genetic instructions and assemble proteins one amino acid at a time. Once a protein is built, it exits the ribosome through a narrow tunnel roughly 100 angstroms long.
Macrolides lodge inside that exit tunnel. For years, scientists assumed they simply plugged it like a cork, blocking all proteins from getting out. The reality is more nuanced. The antibiotic sits in the tunnel and allows some proteins to squeeze past, but when the ribosome tries to link together certain amino acid sequences, the drug interferes with the chemical reaction that forms the bond. Protein assembly stalls, and the bacterium can no longer produce what it needs to function. This makes macrolides bacteriostatic: they don’t kill bacteria outright but halt their growth so the immune system can clear the infection.
What They Treat
Macrolides are a go-to choice for respiratory infections. Doctors prescribe them for community-acquired pneumonia, sinus infections, tonsillitis, and bronchitis. They’re particularly valuable for atypical pneumonia, the kind caused by organisms like Mycoplasma, Legionella, and Chlamydia pneumoniae, because many other common antibiotics don’t reach these pathogens effectively.
Beyond the lungs and sinuses, macrolides are FDA-approved for uncomplicated skin infections and middle ear infections in children. They also play a role in managing flare-ups of chronic obstructive pulmonary disease (COPD). Fidaxomicin, a newer and more specialized macrolide, is used exclusively to treat Clostridioides difficile infections in the gut. Unlike the broader macrolides, fidaxomicin is a narrow-spectrum drug that targets specific bacteria while leaving more of the normal gut flora intact, which helps reduce the high recurrence rates associated with C. difficile.
The Three Main Macrolides Compared
Erythromycin came first, discovered in 1952. It’s effective but has a short half-life of 1.5 to 3 hours, meaning it leaves the bloodstream quickly and typically needs to be taken multiple times a day. It also tends to cause more stomach upset than its successors and strongly inhibits a liver enzyme called CYP 3A4, which creates a long list of potential drug interactions.
Clarithromycin was developed to improve on erythromycin. It absorbs more predictably, reaches peak blood levels within about two hours, and concentrates heavily in tissues like lung, tonsil, and nasal lining, often at levels several times higher than what’s found in the blood. Its half-life is roughly 2.6 to 2.7 hours. It still inhibits CYP 3A4, though somewhat less aggressively than erythromycin.
Azithromycin is the most commonly prescribed of the three. Its standout feature is a long half-life of 11 to 14 hours in the bloodstream, with tissue concentrations that can be 10 to 100 times higher than serum levels. In lung tissue and immune cells called alveolar macrophages, azithromycin persists for days after a single dose. This is why a typical Z-Pack course is only five days, and why it often requires just one dose per day. Azithromycin also has minimal interaction with the CYP 3A4 enzyme, making it far less likely to interfere with other medications.
Drug Interactions
The most important thing to understand about macrolide interactions is that erythromycin and clarithromycin are the main offenders, while azithromycin is relatively safe on this front. Erythromycin and clarithromycin block CYP 3A4, a liver enzyme responsible for breaking down a wide range of medications. When that enzyme is blocked, other drugs linger in the body longer and reach higher levels than intended.
This matters for several drug categories. Clarithromycin more than doubled the blood levels of triazolam (a sleep aid) in studies, while azithromycin had no effect at all. The combination of clarithromycin with certain heart-rhythm or psychiatric medications, like pimozide, is outright contraindicated because it can dangerously prolong the heart’s electrical cycle. Statin cholesterol drugs, blood thinners like warfarin, and migraine medications containing ergotamine can all be affected. If you take any prescription medications regularly, azithromycin is generally the macrolide least likely to cause a problem, but it’s still worth flagging your full medication list.
Side Effects and Heart Rhythm Risk
The most common side effects of macrolides are gastrointestinal: nausea, stomach cramps, and diarrhea. Erythromycin is the worst offender here, which is one reason newer macrolides largely replaced it for routine prescriptions.
The more serious concern is a heart rhythm effect called QT prolongation, where the heart’s electrical reset between beats takes slightly longer than normal. In rare cases, this can trigger a dangerous arrhythmia. The estimated risk in people without additional heart-related risk factors is very low, likely less than 1 in 100,000. A 2001 FDA review found 10 cardiac events linked to QT changes out of 10 million azithromycin prescriptions. Clarithromycin carries a somewhat greater QT prolongation risk than azithromycin. People with existing heart rhythm disorders, very low potassium or magnesium levels, or those already taking other QT-prolonging medications face the highest risk.
Use During Pregnancy
Macrolides cross the placenta, which naturally raises questions about fetal safety. Research on this topic has produced mixed signals over the years. A widely cited Swedish study reported a possible link between erythromycin and cardiovascular malformations, prompting several Scandinavian countries to discourage macrolide use in pregnant women. However, large-cohort studies spanning more than 50 years have generally found no increased risk of major birth defects with first-trimester use. Data on clarithromycin and azithromycin in pregnancy is more limited but similarly reassuring.
One area of caution involves newborns. Macrolide exposure in very early infancy has been linked to a small increase in risk of pyloric stenosis, a condition where the muscle controlling the stomach outlet thickens and blocks food from passing through. Third-trimester exposure does not appear to raise this risk in a clinically meaningful way.
How Bacteria Resist Macrolides
Bacteria have developed two primary strategies to survive macrolide treatment. The first is target modification: bacteria produce enzymes that chemically alter the ribosomal site where macrolides bind, so the drug can no longer attach. This is the most common resistance mechanism in pathogens like Streptococcus and Staphylococcus species.
The second strategy is efflux, essentially a molecular pump embedded in the bacterial cell wall that actively pushes the antibiotic back out before it can accumulate to effective levels. Some gram-negative bacteria are naturally resistant to macrolides because their outer membrane is already difficult for these drugs to penetrate, and built-in efflux pumps expel whatever small amount gets through. Rising macrolide resistance, particularly in respiratory pathogens, is one reason doctors don’t prescribe them for every infection and may choose a different antibiotic class when resistance rates in a given region are high.